Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.
Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM Jr, Schild SE, Zinner RG. Adjei AA, et al. Among authors: dy gk. J Clin Oncol. 2010 Feb 1;28(4):614-9. doi: 10.1200/JCO.2009.23.6406. Epub 2009 Oct 19. J Clin Oncol. 2010. PMID: 19841321 Free PMC article. Clinical Trial.
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.
Adjei AA, Salavaggione OE, Mandrekar SJ, Dy GK, Ziegler KL, Endo C, Molina JR, Schild SE, Adjei AA. Adjei AA, et al. Among authors: dy gk. J Thorac Oncol. 2010 Sep;5(9):1346-53. doi: 10.1097/JTO.0b013e3181ec18c4. J Thorac Oncol. 2010. PMID: 20651609 Free PMC article. Clinical Trial.
SRC inhibitors.
Dy G. Dy G. J Thorac Oncol. 2010 Dec;5(12 Suppl 6):S466-7. doi: 10.1097/01.JTO.0000391368.41011.81. J Thorac Oncol. 2010. PMID: 21102241 Free article. No abstract available.
MEK/MAPK inhibitors.
Dy G. Dy G. J Thorac Oncol. 2010 Dec;5(12 Suppl 6):S474-5. doi: 10.1097/01.JTO.0000391372.94376.37. J Thorac Oncol. 2010. PMID: 21102245 Free article. No abstract available.
Novel taxanes/epothilones.
Dy G. Dy G. J Thorac Oncol. 2010 Dec;5(12 Suppl 6):S490-1. doi: 10.1097/01.JTO.0000391379.94307.d1. J Thorac Oncol. 2010. PMID: 21102252 Free article. No abstract available.
A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.
Dy GK, Hillman SL, Rowland KM Jr, Molina JR, Steen PD, Wender DB, Nair S, Mandrekar S, Schild SE, Adjei AA; North Central Cancer Treatment Group Study N0326. Dy GK, et al. Cancer. 2010 Dec 15;116(24):5686-93. doi: 10.1002/cncr.25448. Cancer. 2010. PMID: 21218460 Free PMC article. Clinical Trial.
A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.
Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR. Weickhardt A, et al. J Thorac Oncol. 2012 Feb;7(2):419-26. doi: 10.1097/JTO.0b013e31823c5b11. J Thorac Oncol. 2012. PMID: 22237261 Free PMC article. Clinical Trial.
138 results